| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 30.8 | 21.6 |
| Gross profit | 19.9 | 12.2 |
| Profit before tax | 8.2 | 2.2 |
| Net income | 6.7 | 2.2 |
| EPS (diluted, $ a share) | $0.11 | $0.04 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +204.1% |
|---|---|
| Revenue, year on year | +42.6% |
| Gross margin | 64.7% |
| Operating margin | 23.8% |
10-Q filed with the SEC, NASDAQ: PAYS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Paysign, Inc.: key numbers
- Share price
- $9.54Close, Nov 16
- Market cap
- $542M
- Shares outstanding
- 56.85MLatest SEC cover page
- Sector
- Trade & Services
- Industry
- Services-Business Services, NECSIC 7389
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Paysign, Inc.
All →Paysign Financial Results
Paysign reported record third-quarter 2026 revenue of $30.8 million, a 43% increase year-over-year, driven by 110% growth in its Pharma patient affordability segment. The company's operating margin more than tripled to 23.8%, and GAAP net income rose to $6.74 million. Management raised full-year 2026 guidance for gross margin, net income, and Adjusted EBITDA while confirming its revenue outlook.
- Term
- Q3 2026
“This was a strong quarter, with patient affordability continuing to compound. We expanded to 167 active programs and increased the quarterly revenue per program by approximately 32% to $99,524. As that business becomes a larger share of our total revenue, we’re seeing gross margin and operating margin expand together, which is translating into higher Adjusted EBITDA.”
Mark Newcomer, President and CEO
“Patient affordability is driving our business, and we are seeing demand and momentum continue to build. Plasma remains an important part of our business, and our experience as one of the leading processors in the industry has given us the insights to understand the challenges plasma centers face.”
Mark Newcomer, President and CEO
Paysign CEO Mark Newcomer Sells $767K of Stock
Mark Newcomer, CEO, sold 50,000 shares of Paysign, Inc. at $15.34 a share, worth $767K in total on Oct 9, 2026. Shares held after the trade: 9,113,002 (-0.5%).
- Value
- $767K
- Shares
- 50,000
- Price
- $15.34
- Role
- CEO
- Holding change
- -0.5%
- Trade date
- Oct 9, 2026